Avidian Wealth Enterprises LLC acquired a new position in LivaNova PLC (NASDAQ: LIVN) in the undefin

Barclays analyst Christopher Pasquale initiates coverage on LivaNova (NASDAQ:LIVN) with a Overwei

Piper Sandler analyst Adam Maeder reiterates LivaNova (NASDAQ:LIVN) with a Overweight and raises

Needham analyst Mike Matson maintains LivaNova (NASDAQ:LIVN) with a Buy and raises the price targ

LivaNova (NASDAQ:LIVN) raises FY2026 Adj EPS guidance from $4.20-$4.30 to $4.30-$4.40 vs $4.25 analy

LivaNova (NASDAQ:LIVN) reported quarterly earnings of $1.26 per share which beat the analyst consens

Mizuho analyst Anthony Petrone maintains LivaNova (NASDAQ:LIVN) with a Outperform and raises the

Top Wall Street analysts changed their outlook on top names. See the latest analyst ratings and cove

Freedom Capital Markets analyst Keith Hinton initiates coverage on LivaNova (NASDAQ:LIVN) with a

Keybanc analyst Brett Fishbin maintains LivaNova (NASDAQ:LIVN) with a Overweight and raises the p

Barclays analyst Matt Miksic maintains LivaNova (NASDAQ:LIVN) with a Equal-Weight and raises the

Mizuho analyst Anthony Petrone maintains LivaNova (NASDAQ:LIVN) with a Outperform and raises the

Baird analyst David Rescott maintains LivaNova (NASDAQ:LIVN) with a Outperform and lowers the pri

Dow Jones up 500 points, DaVita Inc (DVA) shares rise after better-than-expected earnings and raised

Full-Year 2026 GuidanceLivaNova now expects full-year 2026 revenue to grow between 7.0% and 8.0% (ve

Full-Year 2026 GuidanceLivaNova now expects full-year 2026 revenue to grow between 7.0% and 8.0% (ve

LivaNova (NASDAQ:LIVN) reported quarterly earnings of $0.98 per share which beat the analyst consens

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that the jo

– First and only hypoglossal nerve stimulation therapy approved in the U.S. without complete concent

Barclays analyst Matt Miksic maintains LivaNova (NASDAQ:LIVN) with a Equal-Weight and raises the

Needham analyst Mike Matson maintains LivaNova (NASDAQ:LIVN) with a Buy and raises the price targ

LivaNova (NASDAQ:LIVN) is looking for FY2026 Adj EPS of $4.15-$4.25 vs $4.13 analyst estimate. sees

LivaNova (NASDAQ:LIVN) reported quarterly earnings of $0.86 per share which beat the analyst consens

Orrum's CŌRE Insights™ analytics platform will be available through an automatic integration for

Barclays analyst Matt Miksic maintains LivaNova (NASDAQ:LIVN) with a Equal-Weight and raises the

Stifel analyst Rick Wise maintains LivaNova (NASDAQ:LIVN) with a Buy and raises the price target

Keybanc analyst Brett Fishbin initiates coverage on LivaNova (NASDAQ:LIVN) with a Overweight rati

Mizuho analyst Anthony Petrone maintains LivaNova (NASDAQ:LIVN) with a Outperform and raises the

Eight scientific posters demonstrate significant seizure reduction and improved outcomes with VNS Th

Mizuho analyst Anthony Petrone maintains LivaNova (NASDAQ:LIVN) with a Outperform and raises the

Baird analyst David Rescott maintains LivaNova (NASDAQ:LIVN) with a Outperform and raises the pri

Provides 2030 Targets for Revenue and EPS GrowthLivaNova PLC (NASDAQ:LIVN), a market-leading medical

LivaNova (NASDAQ:LIVN) reported quarterly earnings of $1.11 per share which beat the analyst consens

Barclays analyst Matt Miksic maintains LivaNova (NASDAQ:LIVN) with a Equal-Weight and raises the

LivaNova (NASDAQ:LIVN) raises FY2025 Adj EPS guidance from $3.60-$3.70 to $3.70-$3.80 vs $3.65 analy

LivaNova (NASDAQ:LIVN) reported quarterly earnings of $1.05 per share which beat the analyst consens

This is the latest prospective evaluation of VNS Therapy in generalized tonic-clonic seizuresFinding

Final critical papers on RECOVER clinical study data accepted, supporting the Company's submissi

Wolfe Research analyst Mike Polark upgrades LivaNova (NASDAQ:LIVN) from Peer Perform to Outperfor

Barclays analyst Matt Miksic maintains LivaNova (NASDAQ:LIVN) with a Equal-Weight and lowers the

Baird analyst David Rescott maintains LivaNova (NASDAQ:LIVN) with a Outperform and raises the pri